Real-Time Update: Mind Medicine Inc (MNMD) Stock Navigates the Market with Up-to-Date Data

The stock of Mind Medicine Inc (MNMD) has seen a -13.44% decrease in the past week, with a 16.26% gain in the past month, and a 20.27% flourish in the past quarter. The volatility ratio for the week is 7.35%, and the volatility levels for the past 30 days are at 10.34% for MNMD. The simple moving average for the past 20 days is -8.52% for MNMD’s stock, with a -5.86% simple moving average for the past 200 days.

Is It Worth Investing in Mind Medicine Inc (NASDAQ: MNMD) Right Now?

Additionally, the 36-month beta value for MNMD is 1.69. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for MNMD is 27.25M and currently, short sellers hold a 36.90% ratio of that float. The average trading volume of MNMD on December 05, 2024 was 1.10M shares.

MNMD) stock’s latest price update

Mind Medicine Inc (NASDAQ: MNMD) has experienced a decline in its stock price by -4.41 compared to its previous closing price of 7.48. However, the company has seen a fall of -13.44% in its stock price over the last five trading days. businesswire.com reported 2024-12-05 that NEW YORK–(BUSINESS WIRE)–Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been granted an Innovation Passport for the potential treatment of GAD under ILAP by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). The Innovation Passport is the.

Analysts’ Opinion of MNMD

Many brokerage firms have already submitted their reports for MNMD stocks, with Leerink Partners repeating the rating for MNMD by listing it as a “Outperform.” The predicted price for MNMD in the upcoming period, according to Leerink Partners is $20 based on the research report published on October 14, 2024 of the current year 2024.

ROTH MKM, on the other hand, stated in their research note that they expect to see MNMD reach a price target of $36. The rating they have provided for MNMD stocks is “Buy” according to the report published on July 24th, 2024.

Robert W. Baird gave a rating of “Outperform” to MNMD, setting the target price at $27 in the report published on May 29th of the current year.

MNMD Trading at 6.53% from the 50-Day Moving Average

After a stumble in the market that brought MNMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.49% of loss for the given period.

Volatility was left at 10.34%, however, over the last 30 days, the volatility rate increased by 7.35%, as shares surge +6.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.13% upper at present.

During the last 5 trading sessions, MNMD fell by -13.32%, which changed the moving average for the period of 200-days by +54.98% in comparison to the 20-day moving average, which settled at $7.82. In addition, Mind Medicine Inc saw 95.36% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MNMD starting from Sullivan, Mark, who proposed sale 4,430 shares at the price of $5.98 back on Sep 25 ’24. After this action, Sullivan, Mark now owns shares of Mind Medicine Inc, valued at $26,487 using the latest closing price.

Liao Carrie, the Chief Accounting Officer of Mind Medicine Inc, sale 2,352 shares at $5.98 during a trade that took place back on Sep 25 ’24, which means that Liao Carrie is holding 99,543 shares at $14,065 based on the most recent closing price.

Stock Fundamentals for MNMD

Current profitability levels for the company are sitting at:

  • -19.36 for the present operating margin
  • 0.73 for the gross margin

The net margin for Mind Medicine Inc stands at -20.22. The total capital return value is set at -0.33. Equity return is now at value -54.61, with -42.40 for asset returns.

Based on Mind Medicine Inc (MNMD), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -3.02. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -57.57.

Currently, EBITDA for the company is -92.57 million with net debt to EBITDA at 2.86. When we switch over and look at the enterprise to sales, we see a ratio of 52.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.00.

Conclusion

In conclusion, Mind Medicine Inc (MNMD) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts